Streetbeat News

Regulatory

FMS

Fresenius Medical Care has announced that its Versi HD with GuideMe Software has received FDA clearance. The software provides graphical walk-through guidance to enhance ease of use and confidence for both patients and nurses. It is designed to improve patient training time, ease the transition to home, and make the training experience easier for new users.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 1:04 pm

NKLA

Nikola Corp has filed for the resale of up to 10.27 million shares by selling stockholders. The company will not receive any proceeds from these sales. This follows an agreement to sell up to $325 million in senior convertible notes, expected to generate net proceeds of approximately $124.5 million. Nikola shares are down approximately 34% year-to-date and more than 76% over the last year, with increased selling pressure following a fire near its headquarters and a subsequent voluntary recall of over 200 vehicles.

Portfolio Pulse from Adam Eckert

August 23, 2023 | 1:00 pm

ALEAF

RWBYF

The Ontario Superior Court of Justice has approved a stalking horse asset purchase and share subscription agreement where Red White & Bloom Brands Inc. (OTC:RWBYF) (CSE:RWB) would acquire certain assets from Aleafia Health Inc. (OTCPK:ALEAF) and subscribe for shares of certain subsidiaries of Aleafia Health. The agreement is part of Aleafia's proceedings under the Companies’ Creditors Arrangement Act. The deal is subject to certain conditions, including court approval, regulatory approvals, and the licenses being in good standing.

Portfolio Pulse from Vuk Zdinjak

August 23, 2023 | 12:57 pm

IMMX

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Immix Biopharma's NXC-201 for the treatment of multiple myeloma. The designation qualifies NXC-201 for 7 years of U.S. market exclusivity after approval, tax credits for qualified clinical testing, and a waiver of the Prescription Drug User Fee. The multiple myeloma market, valued at $13.9 billion in 2017, is expected to reach $28.7 billion in 2027.

Portfolio Pulse from Happy Mohamed

August 23, 2023 | 12:39 pm

LBPH

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) has completed enrollment for its Phase 1b/2a clinical trial, the PACIFIC Study, which is evaluating LP352 for the treatment of Developmental and Epileptic Encephalopathies (DEEs). The study has enrolled 52 participants and aims to assess the safety and tolerability of LP352. Topline results are expected around year-end 2023.

Portfolio Pulse from Happy Mohamed

August 23, 2023 | 12:31 pm

ADIL

Adial Pharmaceuticals has regained compliance with Nasdaq's listing requirements, thereby avoiding potential delisting.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 12:31 pm

WRNT

Warrantee has received a notification of deficiency from Nasdaq due to its failure to timely file its annual report on Form 20-F.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 12:17 pm

NDRA

ENDRA Life Sciences has been issued three new patents in the U.S. and Europe, strengthening the proprietary position of its TAEUS system. The patents relate to a novel radio frequency applicator, a method and system for monitoring tissue temperature during surgical procedures, and a method and system for determining fractional fat content of tissue. The company's portfolio now includes 67 issued patents globally.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 12:09 pm

VRNOF

Verano Holdings Corp. (CSE:VRNO) (OTCQX:VRNOF) has sued the Alabama Medical Cannabis Commission (AMCC) over the revocation and re-awarding of its Integrated Facility License. Verano initially secured the license in June but lost it in August when the AMCC chose Insa Alabama LLC instead. Verano argues that the commission's actions exceed its statutory authority. The AMCC plans to redo its licensing process again on Aug. 31.

Portfolio Pulse from Jelena Martinovic

August 23, 2023 | 12:07 pm

ABNB

BKNG

New York City's stricter short-term rental regulations have led to a significant decline in Airbnb, Inc (NYSE:ABNB) listings. The new rules, which come into effect on September 5, require hosts to register with the city and be present during guests' stays. Airbnb has blocked future bookings post this timeline. The regulations could also impact other platforms like Vrbo and Booking.com (NASDAQ:BKNG) as they could face penalties for processing payments for unregistered transactions.

Portfolio Pulse from Anusuya Lahiri

August 23, 2023 | 12:03 pm